October 29, 2018 / 7:06 AM / 18 days ago

BRIEF-Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease

Oct 29 (Reuters) - Grifols SA:

* SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER’S DISEASE (AD) PATIENTS

* THE RESULTS IN THE PRESPECIFIED COHORT OF THE PATIENTS SHOWED A REDUCTION OF 61% IN DISEASE PROGRESSION IN BOTH PRIMARY EFFICACY ENDPOINTS MEASURING COGNITION AND ACTIVITIES OF DAILY LIVING DURING A 14 MONTH PERIOD

* AMBAR (ALZHEIMER MANAGEMENT BY ALBUMIN REPLACEMENT) AIMS TO EVALUATE WHETHER AD CAN BE STABILIZED BY PERIODICALLY EXTRACTING PLASMA AND REPLACING IT WITH ALBUMIN

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below